Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Harpoon Therapeutics Inc (HARP)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Harpoon Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Harpoon Therapeutics historical data, for real-time data please try another search
23.01 +0.00    +0.00%
08/03 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 23.00 / 23.01
  • Day's Range: 22.99 - 23.02
Harpoon Therapeutics 23.01 +0.00 +0.00%

Harpoon Therapeutics Inc Company Profile

 
Get an in-depth profile of Harpoon Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

53

Equity Type

ORD

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Contact Information

Address 131 Oyster Point Boulevard Suite 300
South San Francisco, 94080
United States
Phone 650 443 7400
Fax -
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HARP Comments

Write your thoughts about Harpoon Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Carlos Huacoto
Carlos Huacoto Nov 09, 2023 11:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
when reports ? it was not 8 no 9 ? 13 maybe ?
Jack Belforte
Jack Belforte Jun 05, 2023 7:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stock may be breaking away from the pennies and moving to the dollars? Investors rising.
Jack Belforte
Jack Belforte May 31, 2023 5:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Picking away as the chart develops in the 60s after a nice run to the 80s . Bullish
Jack Belforte
Jack Belforte May 18, 2023 5:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Breakout candidate potential growing. HARP
Jack Belforte
Jack Belforte May 17, 2023 6:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HARP eventually gets on radar and climbs over the $1.00
Jack Belforte
Jack Belforte May 10, 2023 10:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HARP may be cracking the $1. 50 area as the stock gets more bids. Buy and hold for 2024.
Jack Belforte
Jack Belforte May 08, 2023 6:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$1.25 from $.55. Will HARP be able to transition over next few weeks?
Jack Belforte
Jack Belforte May 03, 2023 8:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to nibble at lows.
Jack Belforte
Jack Belforte Apr 10, 2023 6:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HARP back into the buy zone here.
Jack Belforte
Jack Belforte Mar 31, 2023 11:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HARP could climb over the dollar mark in the next few weeks.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email